Gastrointestinal manifestations in patients with coronavirus disease-2019 (COVID-19): Impact on clinical outcomes.
Coronavirus
coronavirus disease-2019
gastrointestinal manifestations
severe acute respiratory syndrome coronavirus-2
Journal
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
ISSN: 1735-1995
Titre abrégé: J Res Med Sci
Pays: India
ID NLM: 101235599
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
07
2021
revised:
23
10
2021
accepted:
10
11
2021
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
In this study, we summarized the data on gastrointestinal (GI) involvement and the potential association with clinical outcomes among the patients admitted to Khorshid Hospital. We investigated 1113 inpatients (≥18 years old) diagnosed with coronavirus disease-2019 (COVID-19) from March to June 2020 in Khorshid Hospital. We collected demographic details, clinical information, vital signs, laboratory data, treatment type, and clinical outcomes from patients' medical records. The data of patients with GI symptoms were compared with those without GI symptoms. A total of 1113 patients were recruited (male = 648). GI symptoms were observed in 612 (56.8%) patients (male = 329), the most common of which were nausea 387 (34.7%), followed by diarrhea 286 (25.7%), vomiting 260 (23.4%), and abdominal pain 168 (15.0%). The most prominent non-GI symptoms were cough 796 (71.5%), fever 792 (71.2%), shortness of breath 653 (58.7%), and body pain 591 (53.1%). The number of patients who were discharged, died, and were admitted to intensive care unit was significantly different in groups on the basis of GI and non-GI symptoms ( While COVID-19 was predominantly diagnosed in males, GI symptoms were more commonly reported by females. The results indicated that GI symptoms in COVID-19 patients are common, and the symptoms are not correlated with the severity of the disease. Moreover, the presence of GI symptoms was positively related to milder disease. Among COVID-19 positive patients, the clinical outcomes of the GI group were promising, compared to those of non-GI group.
Sections du résumé
Background
UNASSIGNED
In this study, we summarized the data on gastrointestinal (GI) involvement and the potential association with clinical outcomes among the patients admitted to Khorshid Hospital.
Materials and Methods
UNASSIGNED
We investigated 1113 inpatients (≥18 years old) diagnosed with coronavirus disease-2019 (COVID-19) from March to June 2020 in Khorshid Hospital. We collected demographic details, clinical information, vital signs, laboratory data, treatment type, and clinical outcomes from patients' medical records. The data of patients with GI symptoms were compared with those without GI symptoms.
Results
UNASSIGNED
A total of 1113 patients were recruited (male = 648). GI symptoms were observed in 612 (56.8%) patients (male = 329), the most common of which were nausea 387 (34.7%), followed by diarrhea 286 (25.7%), vomiting 260 (23.4%), and abdominal pain 168 (15.0%). The most prominent non-GI symptoms were cough 796 (71.5%), fever 792 (71.2%), shortness of breath 653 (58.7%), and body pain 591 (53.1%). The number of patients who were discharged, died, and were admitted to intensive care unit was significantly different in groups on the basis of GI and non-GI symptoms (
Conclusion
UNASSIGNED
While COVID-19 was predominantly diagnosed in males, GI symptoms were more commonly reported by females. The results indicated that GI symptoms in COVID-19 patients are common, and the symptoms are not correlated with the severity of the disease. Moreover, the presence of GI symptoms was positively related to milder disease. Among COVID-19 positive patients, the clinical outcomes of the GI group were promising, compared to those of non-GI group.
Identifiants
pubmed: 35548178
doi: 10.4103/jrms.jrms_641_21
pii: JRMS-27-32
pmc: PMC9081509
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32Informations de copyright
Copyright: © 2022 Journal of Research in Medical Sciences.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Cureus. 2020 Mar 21;12(3):e7355
pubmed: 32328367
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2366-2368.e3
pubmed: 32437870
J Microbiol Immunol Infect. 2020 Jun;53(3):384-385
pubmed: 32249184
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):629-630
pubmed: 32405602
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Aliment Pharmacol Ther. 2020 May;51(9):843-851
pubmed: 32222988
Am J Gastroenterol. 2020 May;115(5):766-773
pubmed: 32287140
J Res Med Sci. 2021 Jun 30;26:41
pubmed: 34484373
Gastroenterology. 2020 Jul;159(1):373-375.e2
pubmed: 32294477
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1663-1672
pubmed: 32278065
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Gastroenterol. 2020 Jun;115(6):916-923
pubmed: 32301761
J Med Virol. 2020 Nov;92(11):2735-2741
pubmed: 32510173
PLoS One. 2020 Nov 5;15(11):e0241537
pubmed: 33151983
Gut. 2020 Jun;69(6):1002-1009
pubmed: 32213556
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Gut. 2020 Jun;69(6):997-1001
pubmed: 32241899
World J Gastroenterol. 2020 Apr 14;26(14):1546-1553
pubmed: 32327904
Dig Dis. 2020;38(5):373-379
pubmed: 32599601
Clin Res Hepatol Gastroenterol. 2020 Oct;44(5):653-661
pubmed: 32418852
Gastroenterology. 2020 May;158(6):1518-1519
pubmed: 32142785
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2378-2379.e1
pubmed: 32497637
Clin Infect Dis. 2021 Dec 6;73(11):e4208-e4213
pubmed: 32173725